Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | PLAT | P00750 | 1/20 | 0.53 |
| ▸ | KLK1 | P06870 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | TDP2 | O95551 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31484753 | 1.00 | CYP2A6 (0.63) | CYP2A6CYP1A2ALDH1A1CYP3A4HPGD | |
| SCHEMBL5748743 | 0.84 | TDP1 (0.52) | CYP2A6CYP1A2ALDH1A1CYP3A4HPGD | |
| SCHEMBL5751285 | 0.84 | TDP1 (0.52) | CYP2A6CYP1A2ALDH1A1CYP3A4HPGD | |
| SCHEMBL31484741 | 0.83 | CYP1A2 (0.63) | CYP2A6CYP1A2ALDH1A1CYP3A4HPGD | |
| SCHEMBL4088386 | 0.83 | CYP1A2 (0.63) | CYP2A6CYP1A2ALDH1A1CYP3A4HPGD | |
| SCHEMBL29498396 | 0.77 | CTDSP1 (0.63) | CYP1A2ALDH1A1CYP3A4HPGDHSD17B10 | |
| SCHEMBL29470563 | 0.77 | CYP1A2 (1.00) | CYP2A6CYP1A2ALDH1A1CYP3A4HPGD | |
| SCHEMBL597735 | 0.77 | CYP1A2 (1.00) | CYP2A6CYP1A2ALDH1A1CYP3A4HPGD | |
| SCHEMBL29405526 | 0.77 | CTDSP1 (0.63) | CYP1A2ALDH1A1CYP3A4HPGDHSD17B10 | |
| SCHEMBL729842 | 0.77 | CTDSP1 (0.63) | CYP1A2ALDH1A1CYP3A4HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583852-B2 | Heterocycle derivative | JW PHARMACEUTICAL CORPORATION (KR) | 2026-03-24 | — | — | US | disclosed |
| US-12083498-B2 | Chromatographic materials for the separation of unsaturated molecules | WATERS TECHNOLOGIES CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| CN-111644164-B | Chromatographic material for separating unsaturated molecules | 沃特世科技公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023177216-A1 | ORGANIC ELECTRIC ELEMENT INCLUDING COMPOUND FOR ORGANIC ELECTRIC ELEMENT, AND ELECTRONIC DEVICE THEREOF | 덕산네오룩스 주식회사 | 2023-09-21 | — | — | WO | disclosed |
| US-20230172064-A1 | HETEROCYCLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-01 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20220259199-A1 | NOVEL HETEROCYCLE DERIVATIVE | JW PHARMACEUTICAL CORPORATION (KR) | 2022-08-18 | — | — | US | disclosed |
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021113698-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| EP-3822270-A1 | NOVEL HETEROCYCLE DERIVATIVE | JW Pharmaceutical Corporation (KR) | 2021-05-19 | — | — | EP | disclosed |
| EP-1022274-A1 | Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5977365-A | HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5962470-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5886014-A | TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
| US-4898978-A | Process for the preparation of N,N'-disubstituted guanidines | AKZO N.V. (NL) | 1990-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | CYP2A6 4025/4885CYP1A2 4522/4885ALDH1A1 2214/4885 |
| US-20230172064-A1 | HETEROCYCLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | CRY1, NQO1, CYP2E1 | CYP2A6 679/4885CYP1A2 15/4885ALDH1A1 12/4885 |
| US-12583852-B2 | Heterocycle derivative | AR, SRD5A1, NR5A1 | CYP2A6 1162/4885CYP1A2 2196/4885ALDH1A1 1733/4885 |
| US-20220259199-A1 | NOVEL HETEROCYCLE DERIVATIVE | AR, BRDT, NR5A1 | CYP2A6 1429/4885CYP1A2 1199/4885ALDH1A1 734/4885 |
| US-12083498-B2 | Chromatographic materials for the separation of unsaturated molecules | C9, EPHX2, ALOX5 | CYP2A6 539/4885CYP1A2 719/4885ALDH1A1 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.